ABSTRACT BACKGROUND
• Lung cancer is the second most commonly diagnosed malignancy in the U.S.
-221,200 new cases of lung cancer are projected to occur in 2015 (Siegel et al., 2015) • Lung cancer is the leading cause of cancer death in the U.S.
-Cause of more deaths annually than prostate, breast, colon, and pancreatic cancers combined • An estimated 83% of all lung cancers are non-small cell lung cancers (NSCLC) -Approximately 30% of cancers are categorized as squamous, which is associated with lower survival outcomes than nonsquamous NSCLC • The majority of NSCLC patients present with advanced disease, which has poor prognosis -The 5-year survival for metastatic disease is less than 5% (SEER) • The standard treatment for initial therapy of advanced disease involves platinum-based therapy -Pemetrexed and bevacizumab have shown to improve survival outcomes when added to a first-line platinum-based regimen for patients with non-squamous NSCLC • Patients with advanced disease well enough for treatment will require additional therapy as the disease progresses 
METHODS AND ASSUMPTIONS (CONT)
• Other inputs (continued) -Additional treatment-and outcome-related values are listed in 
OBJECTIVES
The objective of this study was to develop a cost-effectiveness model from a third-party payer perspective to evaluate second-line treatment strategies for NSCLC in the U.S. and to investigate the value of ramucirumab + docetaxel (RAM+DOC) across histological subtypes.
METHODS
Model comparators include the most commonly used second-line treatment regimens for NSCLC for which clinical trial data were available in the squamous, non-squamous, and overall population. We used a lifetime horizon, 3% cost discounting rate, and semi-Markov structure to account for time-dependent variation in probabilities of progression-free and overall survival. The structure of the model incorporated 21-day cycles and four health states including second-line treatment, third-line treatment, best supportive (palliative) care, and death. Clinical trial data were supplemented by other published data, when necessary. Probabilistic and one-way sensitivity analyses were conducted to test the robustness of findings.
RESULTS
Based on the results of this cost-effectiveness analysis, RAM+DOC in the second-line treatment of patients may be considered a costeffective option in the non-squamous populations given an oncology willingness-to-pay threshold of $200,000 per life-year gained (ICER=$192, 833 versus docetaxel alone) . For the overall NSCLC population, comparators were limited and the incremental cost effectiveness ratio was slightly higher (ICER=$222,224 versus docetaxel). There were very limited data to evaluate the squamous population, and the ICER for RAM+DOC was high. The lack of complete data in the histological subgroups was a limitation; analyses were only possible for a subset of the comparators of interest.
CONCLUSIONS
The treatment patterns and cost data used to inform this model are USspecific and would require adaptation to be generalizable elsewhere. Depending on the threshold used by the decision maker, RAM+DOC may be a cost-effective option for the overall and non-squamous NSCLC population.
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STUDY OBJECTIVE
• To develop a cost-effectiveness model to evaluate the costs and benefits of second-line treatment strategies for NSCLC in the U.S.
METHODS AND ASSUMPTIONS
• Perspective: Third-party payer -The model considers only direct medical care costs in the U.S.
• Population: The model considers only direct medical care costs in the U.S.
-Previously treated metastatic NSCLC -Patients whose disease has progressed on or after prior therapy -Three approaches were modeled: all NSCLC patients, those with squamous histology, and those with non-squamous histology, respectively • Time horizon: Lifetime (assumed 10 years) • The base case total and incremental costs and effectiveness results are provided in Table 3. • One-way sensitivity analyses found that ramucirumab drug acquisition costs and ramucirumab + docetaxel PFS and OS hazard ratios had the largest impact on model results across all histological subgroups
• Importantly, the REVEL trial was not powered to detect differences at the histological subgroup level; these sensitivity analyses suggest that caution should be used when interpreting the cost-effectiveness by histology
• Probabilistic sensitivity analyses found that as the willingness-to-pay threshold for life-years gained increases, the more likely ramucirumab + docetaxel is to be the preferred treatment option • In the overall, non-squamous, and squamous populations, 27.8%, 32.5%, and 8.0%, respectively, of the 10,000 iterations performed showed ramucirumab + docetaxel to have a net monetary benefit below a willingness-to-pay threshold of $200,000
-Likely due to insufficient data, the net monetary benefit (NMB) is lower for the squamous subgroup a Dominated (extended dominance) means a combination of regimens has both lower total costs and higher life years than the current regimen b Dominated means another regimen has both lower total costs and higher life years than the current regimen
LIMITATIONS
• This study was conducted with U.S.-specific cost, comparator, and treatment pattern inputs that are not generalizable to other countries or regions.
-Additional studies must be conducted to understand the cost effectiveness of ramucirumab + docetaxel outside the U.S.
• While bevacizumab is used in the U.S. in the post-progression setting, there are little data supporting the use of this agent after initial therapy. The only randomized trial identified in the second-line setting includes a combination with erlotinib that is atypical of U.S. treatment patterns.
• Data for the histological subgroups are very limited, and these results must be interpreted with caution -Due to lack of power to detect significant differences by histologic subgroup in the REVEL trial, sensitivity analyses show that the ICER for the squamous population is reduced by 75% when the overall population outcomes are applied
• Healthcare resource use and outcomes in the real world may differ from those reported in randomized trials • Data are limited to randomized trial data, and may have limited generalizability to the patient population that does not meet study eligibility criteria • Based on the results of this cost-effectiveness analysis, ramucirumab + docetaxel in the second-line treatment of patients may be considered a cost-effective option in the overall NSCLC and non-squamous populations given a willingness-to-pay threshold of $200,000 per life-year gained for oncology treatments • In the squamous population, the ICER for ramucirumab + docetaxel was higher, though with limited options in second- 
